Stay updated on Nivolumab for High-Risk Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.

Latest updates to the Nivolumab for High-Risk Prostate Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedUpdated the Study Documents section to include new and revised documents, including Informed Consent Form PDFs and the Study Protocol with the Statistical Analysis Plan, along with IPD sharing information and related indexing terms.SummaryDifference55%

- Check17 days agoChange DetectedThe page's revision tag was updated to v3.6.5, replacing the previous v3.6.4. This reflects a backend update rather than changes to the study data or visible content.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous v3.6.3. This is a minor version update that does not change the study content or user-facing information.SummaryDifference0.1%

- Check53 days agoChange DetectedThe study details page now shows revision v3.6.3, indicating a small maintenance update to the page template rather than changes to the study information.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2 on the page, indicating a newer revision of the ClinicalTrials.gov entry. This is a routine maintenance update that does not change the study details or user-facing content.SummaryDifference0.3%

- Check74 days agoChange DetectedRecruitment status updated to 'No longer looking for participants' and new help sections added (How to Read a Study Record, Common Questions, How to Join a Study). A header label related to Intervention/Treatment was adjusted and the revision footer updated to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Nivolumab for High-Risk Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.